Patent intelligence · US
US 6399087
Propofol formulation with enhanced microbial inhibition
Propofol formulation with enhanced microbial inhibition
Patent details — US 6399087
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jun 4, 2002
- Expiration
- May 30, 2022
- Applicant
- Amphastar Pharmaceuticals, Inc.
- Claims
- 14
- CPC classes
- A61K, A61K31/05, A61K47/24, A61K47/44
Quick answer
US 6399087 (Propofol formulation with enhanced microbial inhibition) is held by Amphastar Pharmaceuticals, Inc.. Status: expired. Granted Jun 4, 2002. Expires May 30, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Amphastar Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/05, A61K47/24, A61K47/44, A61K9/0019, A61P
More from Amphastar Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12383516
Albuterol aerosol suspension formulation for oral inhalation with high amount of green propellant hydrofluoroolefin (HFO) and free of co-solvent
granted -
US 12370241
Nasal powder formulation for treatment of hypoglycemia
granted -
US 12325732
Pro-insulin aspart structure and method for preparing insulin aspart
granted -
US 12226456
Nasal powder formulation for treatment of hypoglycemia
granted -
US 11938089
Medication delivery systems and methods
granted -
US 11524987
Highly purified recombinant human insulin (RHI) API and methods of producing the same
granted -
US 11446360
High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
granted -
US 10851146
Method for preparing liraglutide intermediate polypeptide
granted
Frequently asked questions
What is US patent 6399087?
US 6399087 (Propofol formulation with enhanced microbial inhibition) is held by Amphastar Pharmaceuticals, Inc.. Status: expired. Granted Jun 4, 2002. Expires May 30, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6399087?
Amphastar Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 15 pharmaceutical patents for this assignee.
When does US 6399087 expire?
Our index shows an expiration date of May 30, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.